MA
ADPT icon

MCF Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

MCF Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9K Buy
833
+175
+27% +$2.68K ﹤0.01% 922
2026
Q1 		$9.13K Sell
658
-469
-42% -$7.47K ﹤0.01% 983
2025
Q4 		$18.3K Buy
1,127
+449
+66% +$7.33K ﹤0.01% 714
2025
Q3 		$10.1K Buy
+678
New +$8.26K ﹤0.01% 693

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

MCF Advisors's ADPT Position: Q2 2026 in Review

MCF Advisors increased its Adaptive Biotechnologies (ADPT) stake by 27% in Q2 2026, buying an estimated $2.68K and bringing the position to 833 shares worth $17.9K. The position accounts for ﹤0.01% of the portfolio, ranked #922.

MCF Advisors first reported a position in ADPT in Q3 2025 and has held it in 4 quarters since. The position peaked at $18.3K in Q4 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • MCF Advisors held 833 shares of Adaptive Biotechnologies worth $17.9K as of Q2 2026.
  • MCF Advisors bought 175 Adaptive Biotechnologies shares in Q2 2026, an estimated $2.68K.
  • Adaptive Biotechnologies made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #922 holding.
  • MCF Advisors first reported a position in Adaptive Biotechnologies in Q3 2025 and has held it in 4 quarters since.
  • MCF Advisors's Adaptive Biotechnologies position peaked at $18.3K in Q4 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.